The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...